Patents by Inventor Ellen Potter

Ellen Potter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRF binding protein
    Patent number: 5844080
    Abstract: A Corticotropin Releasing Factor-binding protein (CRF-BP) is isolated and purified sufficient to provide AA sequence data from which the DNA is obtained, which is then used to produce the protein recombinantly. The CRF-BP is useful for modulating the biological activity of CRF, such as reducing the high ACTH levels in mammals caused by excess CRF. The CRF-BP or fragments thereof and/or antibodies to the proteins may be employed in diagnostic assays to determine the levels of CRF, CRF-BP and the ratio of CRF/CRF-BP in a vascular fluid sample. The DNA or subsequence thereof can be used as probes for genetic material in certain assays. The anti-CRF-BP antibodies are also useful to purify the CRF-BP protein and to modulate the biological effect of CRF-BPs proteins.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 1, 1998
    Assignees: The Salk Institute for Biological Studies, The University of Reading
    Inventors: Ellen Potter, Dominic P. Behan, Wolfgang H. Fischer, Elizabeth A. Linton, Philip J. Lowry, Wylie W. Vale, Jr.
  • CRF binding protein antibodies and assays using same
    Patent number: 5733790
    Abstract: Corticotropin Releasing Factor-binding protein (CRF-BP) is produced recombinantly and is useful for modulating the biological activity of CRF. CRF-BP or fragments thereof and/or antibodies to such polypeptides are employed in diagnostic assays to determine the levels of CRF and CRF-BP and the ratio of CRF/CRF-BP in a vascular fluid sample. Following such an assay, pregnancy-related pathological disorders, such as increased risk of premature labor, can be treated, for example, by administering CRF-BP to lower the ratio of CRF/CRF-BP to within a normal range for pregnancy. Anti-CRF-BP antibodies are also useful to purify CRF-BP and to modulate the biological effect of CRF-BPs.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 31, 1998
    Assignees: The Salk Institute for Biological Studies, The University of Reading
    Inventors: Ellen Potter, Dominic P. Behan, Elizabeth A. Linton, Philip J. Lowry, Wylie W. Vale, Jr.
  • DNA encoding CRF binding protein
    Patent number: 5464757
    Abstract: A Corticotropin Releasing Factor-binding protein (CRF-BP) is isolated and purified sufficient to provide AA sequence data from which the DNA is obtained, which is then used to produce the protein recombinantly. The CRF-BP is useful for modulating the biological activity of CRF, such as reducing the high ACTH levels in mammals caused by excess CRF. The CRF-BP or fragments thereof and/or antibodies to the proteins may be employed in diagnostic assays to determine the levels of CRF, CRF-BP and the ratio of CRF/CRF-BP in a vascular fluid sample. The DNA or subsequence thereof can be used as probes for genetic material in certain assays. The anti-CRF-BP antibodies are also useful to purify the CRF-BP protein and to modulate the biological effect of CRF-BPs proteins.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: November 7, 1995
    Assignees: The Salk Institute for Biological Studies, University of Reading
    Inventors: Ellen Potter, Dominic P. Behan, Wolfgang H. Fischer, Elizabeth A. Linton, Philip J. Lowry, Wylie W. Vale, Jr.